Growth axis
Tesamorelin
Egrifta / Egrifta SV / Egrifta WR
- Peptide length
- 44 amino acids
N-terminally modified peptide
Research contextDefined therapeutic evidence
Read the linked studies for their methods and limitations.
A stabilized GHRH analog used in a defined FDA-labeled context to reduce excess abdominal fat in adults with HIV and lipodystrophy.
- Family
- GHRH analog
- Research frame
- GHRH receptor
- Molecular format
- N-terminally modified peptide
Read the evidence
Read the exact formulation label. Evidence in HIV-associated lipodystrophy is not general weight-loss or anti-aging evidence.
Resolve the identity
Egrifta formulations differ in preparation and delivered dose; they are not automatically substitutable. Confirm the N-terminal modification and formulation.